Research Topics
| David Scott MillerSummaryAffiliation: University of Texas Southwestern Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group studyDavid Scott Miller
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Texas, Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, J7 124, Dallas, TX 75390 9032, USA
Gynecol Oncol 98:217-21. 2005....
A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic OncologyDavid Scott Miller
Division of Gynecologic Oncology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Room J7 124, Dallas, TX 75390 9032, USA
Gynecol Oncol 115:443-6. 2009..To estimate the anti-tumor activity of pemetrexed in patients with advanced or recurrent carcinoma of the endometrium and to determine the nature and degree of toxicity...- Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology GroupDavid Scott Miller
University of Texas Southwestern Medical Center at Dallas, TX 75390 9032, USA
Gynecol Oncol 110:65-70. 2008..To estimate the anti-tumor activity of pemetrexed in patients with advanced or recurrent carcinoma of the cervix that failed on higher priority treatment protocols and to determine the nature and degree of toxicity... - Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group StudyDavid Scott Miller
Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, J7 124, Dallas, TX 75390, USA
Gynecol Oncol 96:67-71. 2005..To estimate the antitumor activity of 9-aminocamptothecin (9-AC) in patients with recurrent platinum-"resistant" ovarian cancer; and to determine the nature and degree of toxicity of 9-AC in this cohort of patients... 
Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology GroupDavid S Miller
University of Texas Southwestern Medical Center at Dallas, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Dallas, TX 75390 9032, USA
J Clin Oncol 27:2686-91. 2009..To estimate the antitumor activity of pemetrexed in patients with persistent or recurrent platinum-resistant epithelial ovarian or primary peritoneal cancer and to determine the nature and degree of toxicities...- Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group studyDavid Scott Miller
Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Cancer 98:1664-9. 2003..CONCLUSIONS: A 3-day regimen of topotecan at a dose of 2.0 mg/m(2) per day was generally well tolerated, although the response rate was lower than that for the standard 5-day schedule... - A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group studyDavid Scott Miller
Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9032, USA
Gynecol Oncol 87:247-51. 2002..CONCLUSION: Topotecan at this dose and schedule does not appear to have major activity in patients with advanced or recurrent endometrial carcinoma previously treated with chemotherapy... - Pharmacotherapy of endometrial cancerNicanor I Barrena Medel
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, USA
Expert Opin Pharmacother 10:1939-51. 2009..The lack of an effective, standardized adjuvant treatment for women at a high risk of recurrence has contributed to these disappointing results... - Other primary malignancies in patients with uterine corpus malignancyJacquelyn B Delin
Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9032, USA
Am J Obstet Gynecol 190:1429-31. 2004..That predisposition may not be detected by routine family history... - Gynecologic oncology group trials in uterine corpus malignancies: recent progressDavid Scott Miller
Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX, USA
J Gynecol Oncol 19:218-22. 2008..This article will discuss the background and details of each of these important advances... - Recent progress: gynecologic oncology group trials in uterine corpus tumorsLouise P King
University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9032, USA
Rev Recent Clin Trials 4:70-4. 2009..This article will discuss the background and details of each of these important advances... - Chemo- and radiotherapy in adjuvant management of optimally debulked endometrial cancerDavid Scott Miller
University of Texas Southwestern Medical Center, Dallas, TX, USA
J Natl Compr Canc Netw 7:535-41. 2009..Recent studies have suggested an expanded role for chemotherapy and questioned the benefit of radiation therapy. Ongoing and planned clinical trials should provide clarification... - Hormonal therapy in epithelial ovarian cancerGautam G Rao
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, B 1100 MCN, Nashville, TN 37232 2516, USA
Expert Rev Anticancer Ther 6:43-7. 2006.... - Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group studyAgustin A Garcia
Breast Cancer Program, Cedars Sinai Medical Center, Women s Cancer Research Institute, 8700 Beverly Boulevard Room 290 W, Los Angeles, CA 90048, USA
Gynecol Oncol 96:810-7. 2005.... - Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group studyFranco M Muggia
Division of Medical Oncology, Department of Medicine, Kaplan Cancer Center, New York University Medical Center, New York, NY 10016, USA
Gynecol Oncol 92:639-43. 2004..The objective of this Phase II trial was to evaluate a days 1 and 8 every-21-days schedule and determine its activity in patients who had failed standard chemotherapy... - Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group studyJohn H Edmonson
Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905-0001, USA
Gynecol Oncol 85:507-10. 2002..Despite its low therapeutic index, this novel, possibly interactive, combination may serve as a forerunner to regimens that more efficiently exploit the enhancement of sarcoma cell kill under hypoxic conditions...